Horizon Discovery and Mirna Therapeutics to Test Activities of Tumor Suppressor MicroRNAs
Horizon’s X-MANTM human cell lines will be used to define the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.
One of the challenges that cancer researchers face in developing cancer therapeutics is that of predicting which patient sub-groups will respond to future drug treatments. Horizon’s novel, genetically-defined X-MANTM human cell lines (or “patients-in-a-test-tube”) will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
This project is funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.